SOURCE: Radient Pharmaceuticals Corporation

Radient Pharmaceuticals Corporation

October 19, 2010 08:30 ET

Radient Pharmaceuticals and Gaur Diagno Launch Cancer Education and Screening Program in India

TUSTIN, CA--(Marketwire - October 19, 2010) -  Radient Pharmaceuticals Corporation (RPC) (NYSE Amex: RPC) and its exclusive India-based distribution partner Jaiva Technologies, Inc. (JTI) and Jaiva's Indian subsidiary Gaur Diagno, Pvt Ltd (GDL) announced today the launch of a cancer education and screening program in India -- a key international market where GDL is actively commercializing RPC's Onko-Sure® in vitro diagnostic (IVD) cancer test. The goal of the program is to drive public education; raise market awareness; and offer Onko-Sure® as a commercialized cancer screening test that can potentially help stem the rising cancer epidemic in India.

According to the Cancer Foundation of India, cancer impacts up to 2.5 million people in India annually and the fight against cancer -- in both the public and private healthcare sectors -- is largely restricted to improving diagnostic and treatment facilities throughout the country. Because of this, it has become increasingly vital to enhance activities and programs that support cancer education and offer treatment options to potential and existing cancer patients. 

With the launch of its cancer education and screening program on behalf of RPC, GDL is taking an aggressive leadership role in India with two distinct launch strategies. The first comprises a widespread deployment of GDL's mobile cancer screening laboratory units where Indian-based physicians and other medical staff travel to local towns to provide counseling and education, along with patient screening using RPC's Onko-Sure® IVD cancer test. The second program is focused on Company collaboration with Indian government agencies to establish GDL-sponsored cancer screening and testing facilities directly on-site in government hospitals. Physician-referred general cancer screening will also be conducted at these hospitals and it is anticipated that RPC's Onko-Sure® IVD cancer tests will be administered to patients contacted through the program. The goal of both strategies is to reduce the incidence of cancer in India, and through each program, patients will be provided with registered health cards that will track a patient's health records for future reference and statistical analysis.

RPC's projected Onko-Sure® IVD test kit purchase plan is focused primarily on the ramp-up of the government sponsored cancer testing program. RPC estimates test kit purchases to be approximately US$2 million in FY2011, and US$3 million in FY2012. These estimates are subject to change based on results of the 64-point questionnaire and these figures have the potential to increase if GDL's results show more than 50% of the patients at high-risk when screened through the 64-point questionnaire.

According to Mr. Douglas MacLellan, Executive Chairman and CEO of RPC, "The introduction of GDL's new cancer education and screening program in India is the next most important and major milestone in the commercialization of Onko-Sure® in India. GDL is taking a leadership role in providing a market with 2.5 million cancer patients with not only educational resources and support through this program, but also the potential of early disease detection and on-going monitoring though our USFDA approved Onko-Sure® IVD cancer test."

According to Dr. Umesh Bhatia, CEO of JTI and GDL, "This government screening program is a breakthrough project and we believe a continuous and aggressive approach is necessary if we are to reduce the incidence of cancer in India. We anticipate this is just the beginning of additional large-scale screening programs we employ. GDL is committed to continuing all efforts to work with Indian government agencies with the ultimate goal of reducing cancer rates in this country."

RPC's Onko-Sure® IVD cancer test is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic (IVD) test used for the detection, screening, and monitoring of various types of cancer. The test enables physicians and healthcare professionals to effectively monitor and/or detect certain types of cancers by measuring the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in the blood. FDP levels rise dramatically with the progression of cancer. Onko-Sure® is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer detection and monitoring test. For more information visit

For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company's corporate website at For Investor Relations information contact Kristine Szarkowitz at or 1.206.310.5323.

About Radient Pharmaceuticals:
Headquartered in Tustin, California, Radient Pharmaceuticals is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its Onko-Sure® In Vitro Diagnostic cancer test. The company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease detection; treatment strategy; and the monitoring of disease progression, prognosis, and diagnosis to ultimately improve patient outcomes. Radient Pharmaceutical's current Onko-Sure® cancer test is used to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, perform additional testing, or assist in the selection of therapy. To learn more about our company, people and potentially life-saving cancer test, visit

About Jaiva Technologies and Gaur Diagno:
Jaiva Technologies, headquartered in Houston, TX, and subsidiary Gaur Diagno, headquartered in New Delhi, India, are working to develop and license novel products for life-threatening diseases. Through science and innovation the company aims to develop novel therapies that will significantly impact and extend the quality of life for patients. Part of the company's effort is large-scale screening of populations that result in meaningful and epidemiological slow-down of life threatening diseases, such as cancer. For further information visit

Forward Looking Statements:
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

Contact Information

  • Radient Pharma Contact:
    Kristine Szarkowitz
    Director-Investor Relations
    Email Contact
    Tel: 206.310.5323